Navigation Links
Calithera Biosciences Presents Data for CB-839 in Triple-Negative Breast Cancer Models at the 2013 San Antonio Breast Cancer Symposium
Date:12/12/2013

SOUTH SAN FRANCISCO, Calif., Dec. 12, 2013 /PRNewswire/ -- Calithera Biosciences, a biotechnology company focused on the development of novel cancer therapeutics, today announced the presentation of preclinical data for its lead anti-cancer therapeutic candidate, CB-839, at the 2013 San Antonio Breast Cancer Symposium.  CB-839 is a potent, selective, orally available glutaminase inhibitor that interferes with tumor metabolism and blocks cancer cell growth and survival. 

"Triple-negative breast cancer, which represents 10-20% of all breast cancers, can be aggressive and difficult to treat due to the fact that the current hormonal and HER-2 directed therapies do not work against these tumors.  Recent data indicate that triple-negative tumor growth is driven in part by high glutaminase expression and a reliance on the conversion of glutamine into glutamate to provide fuel for growth.  CB-839 demonstrates potent inhibition of glutaminase and significant anti-tumor activity in triple-negative breast cancer models, both as a single agent and in combination with the standard-of-care drug paclitaxel," said Susan Molineaux, Ph.D., President and Chief Executive Officer of Calithera Biosciences.  "This research also highlights the potential for use of biomarkers to identify patients whose breast cancer is most likely to respond to CB-839 treatment.  We look forward to advancing CB-839 into Phase 1 clinical studies in patients with advanced triple-negative breast cancer and other solid tumors early next year."

The anti-tumor activity of CB-839 was evaluated in a panel of breast tumor cell lines that included both triple-negative breast cancer and hormone receptor-positive subtypes.  Triple-negative breast cancers displayed higher sensitivity to CB-839 treatment, and this sensitivity was correlated with high glutaminase expression relative to tumor cells that were est
'/>"/>

SOURCE Calithera Biosciences
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Calithera Biosciences Secures $35 Million in Series D Financing
2. Pressure BioSciences, Inc. and Target Discovery, Inc. Expand Strategic License Agreement and Collaboration Supporting TDIs Planned Offering of Personalized Medicine Clinical Diagnostic Services
3. Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2012 Financial Results
4. Amarantus BioSciences to Present at the New York Biotechnology Association (NYBA) 21st Annual Meeting on May 2nd, 2012
5. Neurocrine Biosciences Reports First Quarter 2012 Results
6. Pressure BioSciences, Inc. to Discuss First Quarter 2012 Financial Results And Provide Business Update
7. Ambit Biosciences and Teva Announce Clearance of an Investigational New Drug (IND) Application for CEP-32496, A Novel BRAF(V600E) Inhibitor
8. Neurocrine Biosciences to Present at the Jefferies 2012 Global Healthcare Conference
9. 3-V Biosciences To Present at the Seventh Annual JMP Securities Healthcare Conference
10. Sofie Biosciences receives $1M Phase II SBIR grant from the DOE
11. Frost & Sullivan 2012 New Product Innovation in Bioanalytics Awarded to Protea Biosciences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... , Sept. 22, 2014 ... the U.S. commercial launch of its foot plating system ... Paragon 28.  The GORILLA TM R3CON PLATING SYSTEM ... the Monster TM & Mini-Monster TM Screw ... Comprised of 10 interchangeable subsystems, the GORILLA TM ...
(Date:9/22/2014)... Research and Markets ( ... the  "Global Remotes Market 2014-2018"  report to ... Remotes/remote controls are devices that ... such as smart TVs, set top boxes, ... distance. Remote controls are small wireless handheld ...
(Date:9/22/2014)... -- Final shortlist announced, winners to ... The second edition of the much-awaited VCCircle Healthcare Awards is round ... final nominations for the 2014 honours.  The names of ... 25 at The Taj Mahal Palace, Mumbai . The ... variety of qualitative and quantitative parameters - such as ...
Breaking Medicine Technology:Paragon 28, Inc. Launches the GORILLA(TM) R3CON PLATING SYSTEM 2Global Remotes Market 2014-2018 2Global Remotes Market 2014-2018 3Recognising Impactful Healthcare Companies at VCCircle Healthcare Awards 2014 2Recognising Impactful Healthcare Companies at VCCircle Healthcare Awards 2014 3
... LYON, France, May 11, 2012 Mylan Inc. (Nasdaq: ... launched Atorvastatin Calcium Tablets, 10 mg, 20 mg, 40 ... the Netherlands and Ireland. Mylan has received marketing authorization ... its product immediately. Atorvastatin Calcium is the generic version ...
... /PRNewswire-iReach/ -- Electrochemical Oxygen Concepts (EO2™ ... chronic wound treatment device, announced it has been ... Federal Supply Schedule (FSS) contract, administered by The ... ® , a noninvasive, electrochemical low-dose tissue oxygenation ...
Cached Medicine Technology:Mylan Launches Generic Lipitor® in Five European Countries 2New Chronic Wound Treatment Device Receives Award from Veterans Healthcare Program 2New Chronic Wound Treatment Device Receives Award from Veterans Healthcare Program 3
(Date:9/22/2014)... (PRWEB) September 22, 2014 Airbus Helicopters ... industry Monday for their efforts to improve safety and ... Award and the Program of the Year award, both ... Air Medical Transport Conference Annual Community Awards. , ... with the Jim Charlson Aviation Safety Award, given annually ...
(Date:9/22/2014)... September 22, 2014 Starbrite Dental ... patients who require orthodontic work. Six-Month Smiles is designed ... deserve in a fast and effective way. , Many ... extremely daunting. Having to wear metal braces for several ... and spend time keeping the braces clean, is undesirable ...
(Date:9/22/2014)... (PRWEB) September 22, 2014 United ... all of the federal mesh lawsuits ( http://www.meshinjurylawfirm.com/lawsuits/ ... have been consolidated for pretrial matters, issued an ... Corp. Pelvic Repair System Products Liability Litigation (United ... West Virginia; Case no. 2:12-md-02326)—requiring that four member ...
(Date:9/22/2014)... more and drink more , Study used smartphones to ... differ from past research on physical activity and exercise ... that on days when people exercise more -- typically ... , This is the only study to use smartphone ... activity and alcohol use. , "Monday through Wednesday people ...
(Date:9/22/2014)... and young adults at risk for sexually transmitted infections ... sexual behaviors, according to new recommendations from the U.S. ... million new sexually transmitted infections such as gonorrhea and ... people between 15 and 24 years old, according to ... Sept. 22 in Annals of Internal Medicine , ...
Breaking Medicine News(10 mins):Health News:Airbus Helicopters Inc. Honors Leaders in Air Medical Industry 2Health News:Airbus Helicopters Inc. Honors Leaders in Air Medical Industry 3Health News:Starbrite Dental Introduces Six-Month Smiles 2Health News:Federal Court Sets Trial Date for Boston Scientific Vaginal Mesh Cases in Florida, the Rottenstein Law Group LLP Reports 2Health News:We drink more alcohol on gym days 2Health News:Behavioral Counseling Urged for Teens, Young Adults at Risk for STDs 2Health News:Behavioral Counseling Urged for Teens, Young Adults at Risk for STDs 3
... statement,is being released by Sr. Carol Keehan, DC, ... Association of the United States (CHA):, The ... provided,today by the Holy See,s Congregation for the ... administered nutrition and,hydration to patients in a persistent ...
... Pharmaceuticals,Inc. (Nasdaq: AMLN ) management will be presenting ... Annual Meeting of the European,Association for the Study of ... PT / 1:30 p.m. CET local time in Amsterdam, ... recordings will be made,available following the event. The webcast ...
... Sept. 13 (HealthDay News) -- It,s under your movie seat ... , But relief may be in sight. This week, researchers ... chewing gum at the BA Festival of Science in York, ... clothes, hair and sidewalks, and preliminary tests indicate that it ...
... Mich., Sept. 14 Stryker,Corporation (NYSE: SYK ) ... conference: September 25, 2007 - 4:30 p.m. Eastern ... York, New York A simultaneous webcast of the ... http://www.stryker.com via the For Investors page. The,presentation for ...
... Sept. 14 Mylan Laboratories Inc.,(NYSE: MYL ... Lacerca to the,position of Senior Vice President and ... from Bristol-Meyers Squibb where she was,Director of Compliance ... she was responsible for all compliance-related matters in ...
... WASHINGTON, Sept. 14 - The successful,implementation of electronic ... program $1.2 million per month according to a ... and increased quality,demonstrated in Mississippi reinforces the importance ... Management Association,(PCMA) said today., "The state of ...
Cached Medicine News:Health News:Comment Regarding Congregation for the Doctrine of Faith Clarification Concerning Nutrition and Hydration for Patients in a Persistent Vegetative State 2Health News:Stryker to Present at Investor Conference 2Health News:Mylan Announces Appointment of M. Fabiana Lacerca as Senior Vice President and Chief Compliance Officer 2Health News:E-Prescribing Saving Mississippi Medicaid $1.2 Million Per Month 2
... Graham-Field has been developing diverse ... 58 years. Our medical-surgical products ... for innovation, quality and customer ... include the Labtron® line of ...
... spill-proof design and effective output, even when ... medical nebulizers are free-standing for easy preparation., ... available., ,All Portex® medication nebulizer products ... feature consistently fine misting and the efficient ...
... a spill-proof design and effective output, even ... All medical nebulizers are free-standing for easy ... are available., ,All Portex® medication nebulizer ... nebulizers feature consistently fine misting and the ...
... with metered dose inhalers., ,ACE ensures ... MDI canisters. Its versatile design allows it ... in conjunction with an endotracheal airway or ... ACE may also be used in conjunction ...
Medicine Products: